Moderna's flu vaccine cleared an important hurdle this week. According to Endpoints News, every member of a key FDA advisory panel voted in favor of the company's flu shot.
The vote came from the Vaccines and Related Biological Products Advisory Committee, the outside group of experts the Food and Drug Administration convenes to weigh in on vaccine products. A unanimous result means the committee found no dissent on the question put before it — a notably strong show of support.
Endpoints News reports that the vaccine reached this point after facing roadblocks from previous agency leadership. In other words, the product's path had not been smooth, and the advisory committee's endorsement marks a turn after earlier resistance inside the agency.
It is worth noting what an advisory committee vote is and is not. These panels provide recommendations to the FDA; they do not themselves grant approval. The agency typically weighs such votes heavily but makes the final regulatory decision on its own. The source item here does not detail the next steps, the timing, or the specific terms of any eventual decision.
Why it matters: a unanimous advisory vote signals that independent experts see the case for Moderna's flu shot favorably, and — coming after earlier resistance from prior agency leadership — it suggests the product may be moving past the obstacles that had slowed it down.